SAN DIEGO, June 9, 2017 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, CEO of Neurocrine Biosciences,
will be presenting at the Goldman Sachs 38th Annual
Global Healthcare Conference in Rancho
Palos Verdes, CA.
The live presentation takes place on Thursday, June 15 at 9:20am PT (12:20pm
ET). The presentation will be webcast and may be
accessed on the Company's website at
http://www.neurocrine.com.
Listeners are encouraged to visit the website approximately 5
minutes prior to the presentation to download or install any
necessary software. A replay of the presentation will be
available on the website approximately one hour after the
conclusion of the event and will be archived for one month.
About Neurocrine Biosciences
Neurocrine Biosciences is a San
Diego based biotechnology company focused on neurologic,
psychiatric and endocrine related disorders. In April of 2017, the
FDA approved INGREZZA® (valbenazine) capsules for the treatment of
adults with tardive dyskinesia (TD). INGREZZA is a novel,
selective vesicular monoamine transporter 2 (VMAT2) inhibitor, and
is the first and only FDA-approved product indicated for the
treatment of adults with TD. The Company markets INGREZZA in
the United States. The Company's
three late-stage clinical programs are: elagolix, a
gonadotropin-releasing hormone antagonist for women's health that
is partnered with AbbVie Inc.; opicapone, a novel, once-daily,
peripherally-acting, highly-selective catechol-o-methyltransferase
inhibitor under investigation as adjunct therapy to levodopa in
Parkinson's patients; and INGREZZA (valbenazine), a novel,
once-daily, selective VMAT2 inhibitor under investigation for the
treatment of Tourette syndrome.
Neurocrine Biosciences, Inc. news releases are available through
the Company's website via the internet at
http://www.neurocrine.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-goldman-sachs-38th-annual-global-healthcare-conference-300471523.html
SOURCE Neurocrine Biosciences, Inc.